Back HIV Treatment Approved HIV Drugs

Approved HIV Drugs

IDWeek 2012: Simplified Protease Inhibitor Monotherapy Fails to Maintain HIV Suppression

A simplified regimen of lopinavir/ritonavir (Kaletra) monotherapy did not keep HIV viral load fully suppressed after patients switched from a standard 3-drug antiretroviral regimen, researchers reported at the IDWeek 2012 conference last week in San Diego.alt

Read more:

ICAAC 2012: Atazanavir Linked to Kidney Stones in People with HIV

HIV positive people taking ritonavir-boosted atazanavir (Reyataz) are more likely to develop kidney stones than those using other antiretroviral medications, according to study data presented at the recent 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco and published in the November 1, 2012 issue of Clinical Infectious Diseases. Another study suggested that darunavir (Prezista) may also raise the risk.alt

Read more:

ICAAC 2012: Simplified Abacavir/Atazanavir Combo Keeps HIV Suppressed, May Help Bones

Substituting abacavir/lamivudine (the drugs in Epzicom) for tenofovir/emtricitabine (the drugs in Truvada) and dropping the ritonavir (Norvir) booster with atazanavir (Reyataz) maintains undetectable HIV viral load and improves biomarkers of bone loss, researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) last month in San Francisco. alt

Read more:

1 in 5 People on Atripla Switch, Usually Due to Central Nervous System Side Effects

One-fifth of all people who start the Atripla (efavirenz/tenofovir/emtricitabine) combination pill eventually may need to change to a different regimen, most often due to neuropsychiatric symptoms such as insomnia, abnormal dreams, dizziness, anxiety, or depression, according to a study described in the July 17, 2012, issue of AIDS. alt

Read more:

DHHS Panel Adds Stribild Quad Pill As Alternative Regimen for Treatment-naive HIV Patients

The U.S. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents issued a statement this week indicating that the newly approved Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) single-tablet regimen has been included as an alternative regimen option for people starting HIV treatment for the first time. alt

Read more: